When was Alsachim founded?

Alsachim was founded in 2005 and raised its 1st funding round 1 year after it was founded.

Where is Alsachim located?

Alsachim is headquartered in Illkirch Graffenstaden, France.

Who is the current CEO of Alsachim?

Jean-Francois Hoeffler of Alsachim. They have also founded 1 company.

How many employees does Alsachim have?

As of May 31, 2026, the latest employee count at Alsachim is 53.

Is Alsachim a funded company?

Alsachim is a funded company, having raised a total of $***** in its 1st and only funding round, a PE round on 2006.

When was the latest funding round of Alsachim?

Alsachim's latest funding was a $***** PE round on 2006, with participation from 1 investor.

Where does Alsachim rank among its competitors?

Alsachim ranks 9th amongst 29 active competitors, of which 6 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was NorthStar Medical Radioisotopes, which secured $10.7M in May, 2025.

Who are the top competitors of Alsachim?

Alsachim's top competitors include Curium, NorthStar Medical Radioisotopes and ARTMS. Among them, NorthStar Medical Radioisotopes secured the most recent funding round in May, 2025.

Alsachim - 2026 Company Profile, Team, Funding & Competitors

Company Details

Alsachim offers the custom synthesis of stable radioisotopes & analytical services for pharmaceutical and biotech companies. Custom synthesis of stable isotopically labeled molecules including pharmaceutical intermediates, isotopically-labeled reference standards, metabolites, peptides. biologically active molecules, etc. And analytical services include HPLC, Mass & NMR analysis.

Website: alsachim.com
Social
Email ID: *****@alsachim.com
Phone Number: +33 **********

Key Metrics

Founded Year

2005

Location

Illkirch Graffenstaden, France

Stage

Acquired

Latest Funding Round

PE, 2006, $*****

Investors

Naxicap

Ranked

9^th among 29 active competitors

Employee Count

53 as on May 31, 2026

Similar Companies

Curium & 32 more

Exit Details

Acquired by Shimadzu (Jun 21, 2017)

View Alsachim's full profile

Alsachim got acquired by Shimadzu on Jun 21, 2017.

Click here to take a look at Alsachim's acquisition in detail

Alsachim has raised funding over 1 round. Its latest funding round was a PE round on 2006 for $*****. 1 investor participated in its latest round. Alsachim has 1 institutional investor.

Here is the list of recent funding rounds of Alsachim:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
2006	8926	PE	3024	4298	5654	6177

Access funding benchmarks and valuations. Sign up today!

View details of Alsachim's funding rounds and investors

The founders of Alsachim is Jean-Francois Hoeffler. Jean-Francois Hoeffler is the CEO of Alsachim.

Here are the details of Alsachim's key team members:

Jean-Francois Hoeffler: Founder & CEO of Alsachim.

View details of Alsachim's Founder profiles and Board Members

Alsachim's employee count trend

Alsachim has 53 employees as of May 26. Here is Alsachim's employee count trend over the years:

Uncover Alsachim's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Alsachim include Curium, NorthStar Medical Radioisotopes and ARTMS. Here is the list of Top 10 competitors of Alsachim, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Curium 2017, Paris (France), Seed	Specialty developer, manufacturer & distributor of radiopharmaceuticals	-	CapVest, Ardian	58/100
2nd	NorthStar Medical Radioisotopes 2006, Madison (United States), Series B	Provider of sourcing, purification, and separation technologies for the Nuclear Medicine market	$15.1M	Hendricks Holding, Stateline Angels & 4 others	58/100
3rd	ARTMS 2013, Vancouver (Canada), Acquired	Provider and developer of radioisotope technologies	$26.6M	Deerfield, Quark Venture & 3 others	46/100
4th	AZI 2017, Bunker Hill (United States), Series C	Developer of radiopharmaceuticals for imaging purposes	$58.3M	-	42/100
5th	Ground Fluor Pharmaceuticals 2012, Lincoln (United States), Series A	Biomedical company developing proprietary new chemistry for the synthesis of pharmaceutical compounds	-	Nebraska, America’s Seed Fund & 2 others	37/100
6th	Am Chemicals 2003, Oceanside (United States), Unfunded	Oligonucleotide synthesis solutions: solid supports, reagents, and expert services	-	-	33/100
7th	CellBion 2010, Seoul (South Korea), Public	Radioactive probes for imaging	-	M Venture Investment, BNH INVESTMENT & 2 others	33/100
8th	Nanovista 2015, Toronto (Canada), Seed	Developing multimodal visualization agents	$2.3M	JLABS, GreenSky	32/100
9th	Alsachim 2005, Illkirch Graffenstaden (France), Acquired	Custom synthesis of stable radioisotopes & analytical services for pharmaceutical and biotech companies	-	Naxicap	31/100
10th	VNIR 2017, Bengaluru (India), Seed	Developer of infra red fluorescence based diagnostic molecules	$724K	C-CAMP, BIRAC & 40 others	30/100